Experimental immune therapy for childhood brain cancer shows early safety signals
NCT ID NCT03334305
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether a personalized vaccine made from a child's own tumor could train their immune system to fight high-grade gliomas. The treatment involved giving back activated immune cells (T-cells) and dendritic cell vaccines after chemotherapy. Only 5 children received the therapy before the study was stopped early, but researchers were able to check for safety and immune responses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Children's of Alabama at UAB
Birmingham, Alabama, 35233, United States
-
UF Health Shands Children's Hospital
Gainesville, Florida, 32608, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a 7-Week brain tumor treatment beat the standard 10-Week plan?
- Could an antiparasitic drug boost radiation against childhood brain tumors?
- Can a simple dye help surgeons see brain tumors in real time?